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If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate. Disease burden with cytoreductive outcomes following debulking surgery and platinum 65 sensitivity are two of the strongest predictors of survival in advanced ovarian cancer 66 (AOC)(1-3). As such, the importance of surgery is reflected in published international 67 guidelines (4, 5) . However, both the United States SEER data and the United Kingdom 68 Cancer registry datasets demonstrate that up to 44% of patients with AOC do not receive 69 optimum therapy (6, 7) . Explanations for such deviations in care include: elderly patients; 70 emergency presentations; unclear histology; significant co-morbidities; as well as patient 71 choice (7) (8) (9) . Investigating the underlying factors for this under-treated group has been 72 difficult with limited data recorded in national databases in these patients compared to their 73 counterparts who receive treatment (9) . 74 75 In contrast, there are numerous publications, mainly single centre based, on the success 76 associated with primary cytoreductive surgery where attempted (10) (11) (12) (13) (14) (15) (16) . In this latter group, 77 survival data is often presented without reference to the population from which they are 78 derived. This makes it impossible to ascertain the selection processes which resulted in the 79 reported patient cohort. Patient selection in AOC between centres can vary by: i) by the 80 proportion of patients selected at each centre to receive any treatment; ii) those managed by 81 primary surgery vs neoadjuvant chemotherapy and; iii) finally by the proportion who 82 following neoadjuvant chemotherapy have debulking surgery. All of these variables may 83 render the population reported showing an excellent outcome (e.g. by selecting only those 84 with a high chance of complete cytoreduction) or a poorer outcome (by a policy that all 85 patients are exposed to primary surgery). Failure to report the proportion of patients 86 receiving each treatment modality therefore risks bias, with centres that routinely operate on 87 patients with more disseminated disease potentially reporting inferior survival data in their 88 surgical arm compared to centres that would routinely manage similar patients with the same 89 tumour load with chemotherapy or palliation. The more aggressive centres may however 90 have superior overall survival (OS) data because they are operating on a greater proportion of 91 patients. We define the denominator as the total number of advanced ovarian cancer cases 92 presenting referred to a specific cancer centre or within the catchment area of a cancer centre 93 and describe the survival shift as the 'denominator effect'. In this study, we evaluate the effect of the denominator on the survival of the total AOC cases 96 in a systematic literature search of published literature and data from our cancer centre. to, the MDT of the regional cancer centre. Referrals to other cancer centres are uncommon 141 and usually occur when a specific second opinion is required often after initial treatment has 142 been implemented. As such, within the UK NHS all women with ovarian cancer within a 143 designated region are likely to be registered with a specified cancer centre.
144
The following data were analysed: age; performance status (PS); age-adjusted Charleston co- other variables differed between these five groups. 157 We performed a systematic search of EMBASE databases between 1996 to Week 03 2017 158 using a combination of text words "ovarian ca*" and Medical Subject Headings "surgery" or Thirteen patients did not complete all their NACT cycles due to either death or intolerance.
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The remaining 91 patients completed all their planned NACT cycles and were subsequently 199 considered for IDS (but did not receive it). Failure to receive IDS was most commonly due 200 to: poor performance status or co-morbidities (n= 30); progressive disease following NACT 201 (n=24); no response to NACT (n=21); patient refusal of IDS (n=7); issues pertaining to 202 disease distribution (n=7); dying prior to IDS (n=1); or, unknown (n=1).
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Patients who did not receive cytoreductive surgery were considered in three groups: (1) all 205 those who did not receive cytoreductive surgery (n=152); (2) those who were fit enough to 206 undergo NACT (but did not necessarily receive it) (n=123); and (3) Five of the 123 patients that were fit enough to undergo NACT declined chemotherapy.
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Seven of the 91 patients that completed NACT and were considered for IDS declined 214 surgery. The median OS for the former group of patients was 6.1 months (95% CI 0.9-11.4) 215 whilst those patients in the latter group had not reached median OS by 33 months of follow 216 up.
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To illustrate the 'denominator effect', we analysed the median OS for the five groups of Comparison of median OS between Group A (patients receiving PDS) and Group E (the total 226 patient cohort) demonstrated a highly statistically significant difference, p= 0.000586. There 227 was a statistically significant difference between OS in Groups B and Group E, p = 0.000353 228 and between Groups C and E, p = 0.039180. (Table 2 and In this study, we highlight the effect of the denominator on survival using our centre survival 244 data and the sparse description of denominators in published literature in AOC. To our 245 knowledge, this is the first study to explicitly define the denominator in AOC and describe its 246 relevance. Our study, demonstrates a significant difference in OS based on the total patient 247 cohort 'denominator'. Presenting denominator data would improve the understanding of the 248 process of patient selection within any given Centre, standardise selection between centres 249 and facilitate reducing selection bias which is inevitable in retrospective studies. Importantly 250 it would also help in understanding the underlying factors that preclude patients from 251 receiving therapy, thus potentially improving outcomes. OS for AOC internationally 252 continues to be poor with a five year survival of 30%(39). Unless we focus our efforts on 253 understanding the whole patient cohort of ovarian cancer, including those that do not receive 254 any treatment, obtaining improvements in OS will remain challenging. In our series, 25.6% of patients with AOC did not receive cytoreductive surgery, 4.9% of 257 whom were too ill to receive any treatment beyond that of palliation (Figure 1) . Such findings 258 are consistent with the UKs National Cancer Data Repository which has on record that 44% 259 of patients diagnosed with AOC in the UK do not receive cytoreductive surgery and 25% do 260 not receive any treatment beyond palliation (7) . Such a high prevalence of undertreated 261 patients is not unique to the UK with comparable corresponding figures from the American 262 National Cancer Database (no surgery in 21% and no chemotherapy in 8.7%) and 263 Surveillance, Epidemiology and End Results (SEER) Database (no surgery in 34.2% and no 264 chemotherapy in 16.5%) (8, 9) . that there will be variation in overall operating rates in nationalised healthcare systems 282 compared to systems with significant patient and provider selection. The total patient 283 denominator, may aid identification of those centres with an unselected patient cohort 284 compared to those treating a predominantly triaged population with good fitness for surgery.
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The lack of total denominator data makes a fallacy of a centre's "cytoreduction rate" or 286 "primary surgery rate".
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The importance of the total patient denominator has been established in numerous nationwide 289 cancer audits in the United Kingdom, such as the "National Bowel Cancer Audit Report"(42) 290 and the "National Oesophago-Gastric Cancer Audit"(43). Such basic data has allowed trends 291 in patients receiving treatment to be followed at a local, regional and national level. Both 292 these registers collect data in not only those who receive surgery but also those that, either 293 due to patient or disease factors, do not. The importance of denominator data for ovarian 294 cancer should be considered no different to these other high risk and aggressive cancers. As an important initial step, we suggest that to enable accurate interpretation of prospective 317 or retrospective cohort surgical studies in AOC, the minimum denominator descriptors that 318 should be provided should include the total number of patients as well as the total number of 319 patients operated on. Indeed, the absence of such denominator data risks a disservice to 320 studies that are innovative in their conclusions.
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In conclusion, the denominator of advanced cancer cases in each centre is critical to 323 understanding selection and survival. This is essential for benchmarking and quality 
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